Normative and Student Comparisons Did Not Supply a Matched Cannabis-Treatment Baseline

Medical cannabis patients matching or outperforming a normative sample and student comparison group does not, by itself, show what those patients would have done without acute treatment. The comparator defines the inference.

The reviewed study used external benchmarks

Eadie and colleagues describe medical cannabis patients assessed with a Brief Neurocognitive Battery and compared with the battery’s normative data and forty non-cannabis-using undergraduate students. The review reports favorable comparisons at the observed post-intake assessments.

A benchmark comparison is not an individualized treatment contrast

External norms describe a reference population. A student comparison describes another selected group. Neither automatically controls for every difference in age, education, health, baseline skill or exposure history. Matching a benchmark does not establish that a participant experienced no change from their own untreated performance.

The result remains useful within its scope

The observations can describe performance relative to the chosen comparators. They cannot independently prove that cannabis enhanced cognition, establish equivalence for all functions or validate a personal driving clearance. This distinction does not assume that the patients were impaired; it identifies what the design can answer. A scientific opinion should state whether the question concerns absolute performance against a norm or a causal effect of treatment, and use a comparison appropriate to that question.

Related analysis: the review’s broader findings and limitations.

Research cited

This analysis draws on the supplied review: Eadie and colleagues (2021). Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in Psychiatry.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Adding CBD in a Small MS Cannabis-Extract Trial Was Associated With More Adverse Events

A small MS trial summarized in the early human CBD review reported more adverse events with a CBD-containing cannabis extract than with THC alone. The combination did not demonstrate a general safety advantage. The study had a defined clinical comparison The review describes a four-week crossover study involving 16 patients…

Spread the love

Read Article: Adding CBD in a Small MS Cannabis-Extract Trial Was Associated With More Adverse Events

A Cancer-Anorexia Cannabis Trial Stopped at Interim Analysis for Lack of Group Differences

A cancer-related anorexia trial summarized in the early human CBD review was terminated at interim analysis because the study arms did not differ. Its combination treatment did not supply positive appetite-treatment evidence in that comparison. The trial compared more than one active preparation The review describes 243 patients assigned to…

Spread the love

Read Article: A Cancer-Anorexia Cannabis Trial Stopped at Interim Analysis for Lack of Group Differences

A CBD–Nabilone Experiment Reported Only Marginal Changes in Intoxication and Depth Perception

A small historical crossover experiment summarized in the human CBD review reported marginal reductions in nabilone-related intoxication and binocular depth-perception impairment. It did not establish broad protection against synthetic-cannabinoid effects. The comparison involved a specific synthetic cannabinoid Nine male participants received oral CBD at 200 mg, alone and with nabilone…

Spread the love

Read Article: A CBD–Nabilone Experiment Reported Only Marginal Changes in Intoxication and Depth Perception

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us